{"filing":{"accession_number":"0001104659-26-086254","cik":"0001781983","ticker":"APRE","company_name":"Aprea Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"tm2621205d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm"},"events":[{"id":20015,"run_id":18020,"accession_number":"0001104659-26-086254","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Aprea Therapeutics received notification from Nasdaq on July 23, 2026, that while it has not yet regained compliance with the $1.00 minimum bid price requirement, it has been granted an additional 180-day compliance period until January 19, 2027. The disclosure explicitly states that if compliance cannot be demonstrated by that date, Nasdaq will provide written notification that the Common Stock will be delisted. This is a classic delisting-risk disclosure under Item 3.01, indicating the company faces imminent delisting if it fails to meet the minimum bid price threshold.","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19267,"accession_number":"0001104659-26-086254","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Aprea Therapeutics received notification from Nasdaq on July 23, 2026, that while it has not yet regained compliance with the $1.00 minimum bid price requirement, it has been granted an additional 180-day compliance period until January 19, 2027. The disclosure explicitly states that if compliance cannot be demonstrated by that date, Nasdaq will provide written notification that the Common Stock will be delisted. This is a classic delisting-risk disclosure under Item 3.01, indicating the company faces imminent delisting if it fails to meet the minimum bid price threshold.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:07:49.977113+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19267,"accession_number":"0001104659-26-086254","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Aprea Therapeutics received notification from Nasdaq on July 23, 2026, that while it has not yet regained compliance with the $1.00 minimum bid price requirement, it has been granted an additional 180-day compliance period until January 19, 2027. The disclosure explicitly states that if compliance cannot be demonstrated by that date, Nasdaq will provide written notification that the Common Stock will be delisted. This is a classic delisting-risk disclosure under Item 3.01, indicating the company faces imminent delisting if it fails to meet the minimum bid price threshold.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:07:49.977113+00:00","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-07-23"}]}